Clinical and molecular markers in COPD (original) (raw)

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease, and there is a clinical need for validated markers and biomarkers that can contribute to the assessment of patients, risk prediction, treatment guidance, and assessment of response. Although according to the 2018 GOLD guidelines clinically useful biomarkers for COPD patients in stable condition have yet to be identified, several clinical markers and biomarkers have been proposed for COPD. These include isolated clinical markers, such as symptoms and Health Status assessment, exercise tests, function tests and imaging, and also composite scores and molecular markers. However, and despite strong efforts to identify useful markers in an attempt to improve prognostic and therapeutic approaches, results have not been consistent and expectations of relying on these markers in near future are faint. Current approaches to COPD have shifted from treating the disease to treating the individual patient. There is a clear need to identify treatable traits, focusing more on the patient and not on the disease, in order to implement an increasingly personalized treatment of COPD in the clinic, leading to true precision medicine. There is a need to identify combinations of clinical markers and biomarkers, genetic markers, and phenotypes that can guide the personalized therapy of COPD patients. This critical review will therefore focus not only on currently established markers and biomarkers in COPD but also on possible future approaches toward precision medicine.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (93)

  1. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised man- agement. Lancet. 2015;385:1789---98.
  2. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410---9.
  3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2018.
  4. Li LS, Caughey GE, Johnston KN. The association between co- morbidities and physical performance in people with chronic obstructive pulmonary disease: a systematic review. Chron Respir Dis. 2014;11:3---13.
  5. Jones PW, Agusti AG. Outcomes and markers in the assess- ment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:822---32.
  6. Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med. 2014;35:131---41.
  7. Morrow DA, de Lemos JA. Benchmarks for the assess- ment of novel cardiovascular biomarkers. Circulation. 2007;115:949---52.
  8. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648---54.
  9. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and respon- siveness of the clinical COPD questionnaire. Health Qual Life Outcomes. 2003;1:13.
  10. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773---8.
  11. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med. 1991;85 Suppl B:25---31, discussion 33-7.
  12. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstruc- tive pulmonary disease. Thorax. 1999;54:581---6.
  13. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434---40.
  14. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstruc- tive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186:975---81.
  15. Tsiligianni IG, van der Molen T, Moraitaki D, Lopez I, Kocks JW, Karagiannis K, et al. Assessing health status in COPD. A head- to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med. 2012;12:20.
  16. Kim S, Oh J, Kim YI, Ban HJ, Kwon YS, Oh IJ, et al. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: A cross-sectional analyses. BMC Pulm Med. 2013;13: 35.
  17. Karloh M, Fleig Mayer A, Maurici R, Pizzichini MM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far? A systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149:413---25.
  18. Fragoso E, Andre S, Boleo-Tome JP, Areias V, Munha J, Cardoso J. Understanding COPD: a vision on phenotypes, comorbidities and treatment approach. Rev Port Pneumol. 2016;22:101---11.
  19. Alibakhshi E, Lores L, Fiorillo R. Physiological factors relevant to exercise tests in pulmonary rehabilitation of COPD patients. J Sports Med Doping Stud. 2015;6:1---12.
  20. Depew ZS, Novotny PJ, Benzo RP. How many steps are enough to avoid severe physical inactivity in patients with chronic obstruc- tive pulmonary disease? Respirology. 2012;17:1026---7.
  21. Troosters T, van der Molen T, Polkey M, Rabinovich RA, Vogiatzis I, Weisman I, et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115.
  22. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, et al. Physical activity is the strongest predictor of all-cause mortal- ity in patients with COPD: a prospective cohort study. Chest. 2011;140:331---42.
  23. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005---12.
  24. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Anto JM, Agusti AG, et al. Expansion of the prognostic assess- ment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374:704---11.
  25. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003;167:544---9.
  26. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23:28---33.
  27. DePew ZS, Garofoli AC, Novotny PJ, Benzo RP. Screening for severe physical inactivity in chronic obstructive pulmonary disease: the value of simple measures and the validation of two physical activity questionnaires. Chron Respir Dis. 2013;10:19---27.
  28. Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB. The Rapid Assessment of Physical Activ- ity (RAPA) among older adults. Prev Chronic Dis. 2006;3: A118.
  29. Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47:429---60.
  30. Puhan MA, Siebeling L, Zoller M, Muggensturm P, ter Riet G. Simple functional performance tests and mortality in COPD. Eur Respir J. 2013;42:956---63.
  31. Bohannon RW. Measurement of sit-to-stand among older adults. Top Geriatr Rehabil. 2012;28:11---6.
  32. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a mea- sure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70:113---9.
  33. Guimaraes M, Bugalho A, Oliveira AS, Moita J, Marques A. COPD control: can a consensus be found? Rev Port Pneumol (2006). 2016;22:167---76.
  34. Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194:541---9.
  35. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Rela- tionship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847---52.
  36. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184---92.
  37. Lange P, Celli B, Agusti A, Boje Jensen G, Divo M, Faner R, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373:111---22.
  38. Zaman M, Mahmood S, Altayeh A. Low inspiratory capac- ity to total lung capacity ratio is a risk factor for chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2010;339:411---4.
  39. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio pre- dicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591---7.
  40. Cebollero P, Zambom-Ferraresi F, Hernandez M, Hueto J, Cas- cante J, Anton MM. Inspiratory fraction as a marker of skeletal muscle dysfunction in patients with COPD. Rev Port Pneumol (2006). 2016.
  41. French A, Balfe D, Mirocha JM, Falk JA, Mosenifar Z. The inspiratory capacity/total lung capacity ratio as a predictor of survival in an emphysematous phenotype of chronic obstruc- tive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1305---12.
  42. Ramon MA, Ferrer J, Gimeno-Santos E, Donaire-Gonzalez D, Rodriguez E, Balcells E, et al. Inspiratory capacity-to-total lung capacity ratio and dyspnoea predict exercise capacity decline in COPD. Respirology. 2016;21:476---82.
  43. Yang H, Xiang P, Zhang E, Guo W, Shi Y, Zhang S, et al. Is hyper- capnia associated with poor prognosis in chronic obstructive pulmonary disease? A long-term follow-up cohort study. BMJ Open. 2015;5:e008909.
  44. Ruppel GL, Enright PL. Pulmonary function testing. Respir Care. 2012;57:165---75.
  45. de-Torres JP, Marin JM, Casanova C, Pinto-Plata V, Divo M, Cote C, et al. Identification of COPD patients at high risk for lung cancer mortality using the COPD-LUCSS-DLCO. Chest. 2016;149:936---42.
  46. Weinreich UM, Thomsen LP, Brock C, Karbing DS, Rees SE. Diffu- sion capacity of the lung for carbon monoxide ---a potential marker of impaired gas exchange or of systemic decondi- tioning in chronic obstructive lung disease? Chron Respir Dis. 2015;12:357---64.
  47. Mohamed Hoesein FA, Zanen P, van Ginneken B, van Klaveren RJ, Lammers JW. Association of the transfer coefficient of the lung for carbon monoxide with emphysema progression in male smokers. Eur Respir J. 2011;38:1012---8.
  48. Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109:785---802.
  49. Thomas M, Decramer M, O'Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J. 2013;22:101---11.
  50. Al-Kassimi FA, Alhamad EH, Al-Hajjaj MS, Raddaoui E, Alzeer AH, Alboukai AA, et al. Can computed tomography and carbon monoxide transfer coefficient diagnose an asthma-like pheno- type in COPD? Respirology. 2016.
  51. Novais e Bastos H, Neves I, Redondo M, Cunha R, Pereira JM, Magalhães A, et al. Influência da distribuic ¸ão do enfisema nos parâmetros de func ¸ão pulmonar em pacientes com DPOC. J Bras Pneumol. 2015;41:489---95.
  52. Wells JM, Iyer AS, Rahaghi FN, Bhatt SP, Gupta H, Denney TS, et al. Pulmonary artery enlargement is associated with right ventricular dysfunction and loss of blood volume in small pul- monary vessels in chronic obstructive pulmonary disease. Circ Cardiovasc Imaging. 2015:8.
  53. Wells JM, Dransfield MT. Pathophysiology and clinical implica- tions of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:509---21.
  54. Ando K, Kuraishi H, Nagaoka T, Tsutsumi T, Hoshika Y, Kimura T, et al. Potential role of CT metrics in chronic obstruc- tive pulmonary disease with pulmonary hypertension. Lung. 2015;193:911---8.
  55. Zagaceta J, Zulueta JJ, Bastarrika G, Colina I, Alcaide AB, Campo A, et al. Epicardial adipose tissue in patients with chronic obstructive pulmonary disease. PLoS ONE. 2013;8:e65593.
  56. Jones RC, Price D, Chavannes NH, Lee AJ, Hyland ME, Stallberg B, et al. Multi-component assessment of chronic obstructive pul- monary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in inter- national primary care data sets. NPJ Prim Care Respir Med. 2016;26:16010.
  57. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50 Suppl 1:1---16.
  58. Molina Paris J. How can we define well-controlled chronic obstructive pulmonary disease? Expert Rev Respir Med. 2013;7:3---15.
  59. Camiciottoli G, Bigazzi F, Bartolucci M, Cestelli L, Paoletti M, Diciotti S, et al. BODE-index, modified BODE-index and ADO- score in chronic obstructive pulmonary disease: relationship with COPD phenotypes and CT lung density changes. COPD. 2012;9:297---304.
  60. Dijk WD, Bemt L, Haak-Rongen S, Bischoff E, Weel C, Veen JC, et al. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res. 2011;12:151.
  61. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson- Spillmann M, Harding S, et al. Derivation and validation of a composite index of severity in chronic obstructive pul- monary disease: the DOSE index. Am J Respir Crit Care Med. 2009;180:1189---95.
  62. Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413---24.
  63. Anzueto AR, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, et al. Indacaterol/glycopyrronium (IND/GLY) delays clinically impor- tant deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis. In: Poster A2331 Presented at the European Respiratory Society International Congress. 2016.
  64. Alonso-Moran E, Nuno-Solinis R, Onder G, Tonnara G. Multimor- bidity in risk stratification tools to predict negative outcomes in adult population. Eur J Intern Med. 2015;26:182---9.
  65. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68:670---6.
  66. Jing Z, Chun C, Ning S, Hong Z, Bei H, Wan-Zhen Y. Systemic inflammatory marker CRP was better predictor of readmission for AECOPD than sputum inflammatory markers. Arch Bron- coneumol. 2016;52:138---44.
  67. Moy ML, Teylan M, Weston NA, Gagnon DR, Danilack VA, Garshick E. Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD. Chest. 2014;145:542---50.
  68. Peng C, Tian C, Zhang Y, Yang X, Feng Y, Fan H. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci. 2013;345:190---4.
  69. Ferrari R, Tanni SE, Caram LM, Correa C, Correa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013;14:24.
  70. Labonte L, Coulombe P, Zago M, Bourbeau J, Baglole CJ. Alter- ations in the expression of the NF-kappaB family member RelB as a novel marker of cardiovascular outcomes during acute exa- cerbations of chronic obstructive pulmonary disease. PLoS ONE. 2014;9:e112965.
  71. Labonte LE, Bourbeau J, Daskalopoulou SS, Zhang M, Coulombe P, Garland K, et al. Club cell-16 and RelB as novel determinants of arterial stiffness in exacerbating COPD patients. PLoS ONE. 2016;11:e0149974.
  72. Miller BE, Tal-Singer R, Rennard SI, Furtwaengler A, Leidy N, Lowings M, et al. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary dis- ease. perspective of the chronic obstructive pulmonary disease biomarker qualification consortium. Am J Respir Crit Care Med. 2016;193:607---13.
  73. Chang Y, Glass K, Liu YY, Silverman EK, Crapo JD, Tal-Singer R, et al. COPD subtypes identified by network-based clustering of blood gene expression. Genomics. 2016;107:51---8.
  74. Antus B. Oxidative stress markers in sputum. Oxid Med Cell Longev. 2016;2016:2930434.
  75. Tzortzaki EG, Dimakou K, Neofytou E, Tsikritsaki K, Samara K, Avgousti M, et al. Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseases. Chest. 2012;141:1243---50.
  76. Christiansen A, Davidsen JR, Titlestad I, Vestbo J, Baumbach J. A systematic review of breath analysis and detection of volatile organic compounds in COPD. J Breath Res. 2016;10:034002.
  77. Santini G, Mores N, Shohreh R, Valente S, Dabrowska M, Trove A, et al. Exhaled and non-exhaled non-invasive markers for assess- ment of respiratory inflammation in patients with stable COPD and healthy smokers. J Breath Res. 2016;10:017102.
  78. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48---55.
  79. Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, et al. Blood eosinophils and out- comes in severe hospitalized exacerbations of COPD. Chest. 2016;150:320---8.
  80. Couillard S, Larivee P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmis- sions. Chest. 2017;151:366---73.
  81. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662---71.
  82. Watz H, Bateman ED, Magnussen H, Kirsten A, Tetzlaff K, Disse B, et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilators: lung function reduc- tion in the WISDOM study. Am J Respir Crit Care Med. 2015;191. A3641.
  83. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390---8.
  84. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, ran- domised controlled trials. Lancet Respir Med. 2013;1:210---23.
  85. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary anal- ysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435---42.
  86. Iyer AS, Dransfield MT. Serum eosinophils as a COPD biomarker: ready for prime time? Lancet Respir Med. 2016;4:341---3.
  87. Chapman KR, Vogelmeier CF, Fowler Taylor A, Ayers T, Thach C, Shrinivasan A, et al. Effect of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on base- line blood eosinophil counts: results from the FLAME study. In: Poster A2318 Presented at the European Respiratory Society International Congress. 2016.
  88. Roche N, Chapman KR, Vogelmeier CF, Herth FJ, Thach C, Fogel R, et al. Blood eosinophils and response to maintenance COPD treatment: data from the FLAME trial. Am J Respir Crit Care Med. 2017.
  89. Calverley PM, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EF, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017.
  90. Ferreira AJ, Reis A, Marcal N, Pinto P, Barbara C. COPD: a stepwise or a hit hard approach? Rev Port Pneumol (2006). 2016;22:214---21.
  91. Wedzicha JA. Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk. maybe just for some? Am J Respir Crit Care Med. 2016;193:937---8.
  92. Ferreira J, Drummond M, Pires N, Reis G, Alves C, Robalo- Cordeiro C. Optimal treatment sequence in COPD: can a consensus be found? Rev Port Pneumol (2006). 2016;22: 39---49.
  93. Agusti A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet. 2017;390:980---7.